Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Scholar Rock Holding Corporation is a biotechnology business based in the US. Scholar Rock Holding Corporation shares (SRRK) are listed on the NASDAQ and all prices are listed in US Dollars. Scholar Rock Holding Corporation employs 93 staff and has a trailing 12-month revenue of around USD$19.5 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
52-week range | USD$10.09 - USD$66.718 |
---|---|
50-day moving average | USD$54.7515 |
200-day moving average | USD$35.1283 |
Wall St. target price | USD$66.25 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-1.947 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Revenue TTM | USD$19.5 million |
---|---|
Gross profit TTM | USD$-33,725,000 |
Return on assets TTM | -25.97% |
Return on equity TTM | -77.38% |
Profit margin | 0% |
Book value | $2.105 |
Market capitalisation | USD$1.7 billion |
TTM: trailing 12 months
There are currently 1.4 million Scholar Rock Holding Corporation shares held short by investors – that's known as Scholar Rock Holding Corporation's "short interest". This figure is 9.4% down from 1.5 million last month.
There are a few different ways that this level of interest in shorting Scholar Rock Holding Corporation shares can be evaluated.
Scholar Rock Holding Corporation's "short interest ratio" (SIR) is the quantity of Scholar Rock Holding Corporation shares currently shorted divided by the average quantity of Scholar Rock Holding Corporation shares traded daily (recently around 229276.61691542). Scholar Rock Holding Corporation's SIR currently stands at 6.03. In other words for every 100,000 Scholar Rock Holding Corporation shares traded daily on the market, roughly 6030 shares are currently held short.
However Scholar Rock Holding Corporation's short interest can also be evaluated against the total number of Scholar Rock Holding Corporation shares, or, against the total number of tradable Scholar Rock Holding Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Scholar Rock Holding Corporation's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Scholar Rock Holding Corporation shares in existence, roughly 40 shares are currently held short) or 0.0709% of the tradable shares (for every 100,000 tradable Scholar Rock Holding Corporation shares, roughly 71 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Scholar Rock Holding Corporation.
Find out more about how you can short Scholar Rock Holding Corporation stock.
We're not expecting Scholar Rock Holding Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Scholar Rock Holding Corporation's shares have ranged in value from as little as $10.09 up to $66.718. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Scholar Rock Holding Corporation's is 0.315. This would suggest that Scholar Rock Holding Corporation's shares are less volatile than average (for this exchange).
Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, a novel inhibitor of the activation of myostatin, which is in Phase II clinical trials for the treatment of spinal muscular atrophy. The company is also developing SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1. In addition, it is developing a pipeline of novel product candidates for a range of serious diseases, including neuromuscular disorders, cancer, fibrosis, and anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.